Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2012

01-10-2012 | Breast Oncology

Balancing Venous Thromboembolism and Hematoma After Breast Surgery

Authors: Jenna K. Lovely, RPh, PharmD, BCPS, Sharon A. Nehring, RN, Judy C. Boughey, MD, Amy C. Degnim, MD, Rajakumar Donthi, M Pharm, PhD, BCPS, William Scott Harmsen, MS, James W. Jakub, MD

Published in: Annals of Surgical Oncology | Issue 10/2012

Login to get access

Abstract

Purpose

The purposes of this study are (1) to determine our institution’s rate of venous thromboembolic events (VTE) and hematomas following breast surgery, and (2) to compare our breast surgery VTE rate with both our general surgery population and the National surgical quality improvement program (NSQIP) dataset.

Methods

Prospectively collected NSQIP data from April 2006 to June 2010 were analyzed. Our institution’s VTE rates, pharmacologic prophylaxis (PCP) utilization, and hematomas were reviewed for patients undergoing breast surgery. The VTE rate was compared with NSQIP patient populations.

Results

Among 4,579 breast operations at our institution over this time period, 988 (21.6 %) were analyzed through NSQIP. The VTE rate following breast operations was 4/988 (0.4 %): 0/236 for those with benign disease and 4/752 (0.5 %) for those with breast cancer (p = 0.58). PCP was received by 147/752 (19.5 %) cancer patients. In cancer patients, the hematoma rate requiring reoperation was 3/147 (2.0 %) in those receiving PCP and 12/605 (2.0 %) in those not receiving PCP (p = 1.0). Breast surgery patients had a similar VTE rate compared with the institutional general surgery population (0.7 %, p = 0.254) and versus national general surgery patients from NSQIP (0.7 %, p = 0.29). Our institution’s VTE incidence for patients with breast cancer undergoing mastectomy was significantly higher than “like” NSQIP centers.

Conclusions

Our breast surgery VTE rate was similar to our general surgery population. Our mastectomy population had a higher VTE incidence compared with other NSQIP sites. Patients undergoing mastectomy, especially if combined with axillary lymph node dissection or reconstruction, should be considered for routine PCP.
Literature
1.
Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010; 199(1 Suppl):S3–10.PubMedCrossRef
2.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edn). Chest. 2008;133(6 Suppl):381S–453S.PubMedCrossRef
3.
Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–77S.PubMedCrossRef
4.
Andtbacka RH, Babiera G, Singletary SE, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006;243(1):96–101.PubMedCrossRef
5.
Clahsen PC, van de Velde CJ, Julien JP, et al. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol. 1994;12(6):1266–71.PubMed
6.
Kirwan CC, McCollum CN, Bundred NJ, Byrne GJ. Current UK practice of thromboprophylaxis for breast surgery. Br J Surg. 2006;93(10):1224–5.PubMedCrossRef
7.
Pannucci CJ, Chang EY, Wilkins EG. Venous thromboembolic disease in autogenous breast reconstruction. Ann Plast Surg. 2009;63(1):34–8.PubMedCrossRef
8.
Patiar S, Kirwan CC, McDowell G, et al. Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg. 2007;94(4):412–20.PubMedCrossRef
9.
Surgeons TASoB. In: Board of Directors TASoBS, editors. Position statement on venous thromboembolism prophylaxis for patients undergoing breast operations. vol. 2012. Phoenix: The American Society of Breast Surgeons; 2011.
10.
Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs’ NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg. 1998;228(4):491–507.PubMedCrossRef
11.
Specific ANP. ACS NSQIP program specific. Variables and definitions. Vol. 2011. ACS; 2011.
12.
Pannucci CJ, Bailey SH, Dreszer G, et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. J Am Coll Surg. 2011;212(1):105–12.PubMedCrossRef
13.
Neumayer L, Schifftner TL, Henderson WG, et al. Breast cancer surgery in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg. 2007;204(6):1235–41.PubMedCrossRef
14.
El-Tamer MB, Ward BM, Schifftner T, et al. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245(5):665–71.PubMedCrossRef
15.
Pannucci CJ, Wilkins EG. Hematoma risk should not preclude the use of venous thromboembolism prophylaxis. Aesthet Surg J. 2009;29(4):338 (author reply 339).
16.
Metadata
Title
Balancing Venous Thromboembolism and Hematoma After Breast Surgery
Authors
Jenna K. Lovely, RPh, PharmD, BCPS
Sharon A. Nehring, RN
Judy C. Boughey, MD
Amy C. Degnim, MD
Rajakumar Donthi, M Pharm, PhD, BCPS
William Scott Harmsen, MS
James W. Jakub, MD
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2524-y

Other articles of this Issue 10/2012

Annals of Surgical Oncology 10/2012 Go to the issue

Breast Oncology

Triangle Resection with Crescent Mastopexy: An Oncoplastic Breast Surgical Technique for Managing Inferior Pole Lesions

Breast Oncology

Atypical Ductal Hyperplasia on Core Biopsy: An Automatic Trigger for Excisional Biopsy?

Breast Oncology

Y-V Oncoplastic Wound Repair of Mastectomy Dog-Ear Deformity

Breast Oncology

The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who Present with Node-Positive Breast Cancer

Breast Oncology

Long-Term Results of Excision Followed by Radiofrequency Ablation as the Sole Means of Local Therapy for Breast Cancer

Breast Oncology

American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns